Our Team
Dr. Somanath Vasudeva
Sr.consultant and
head of the department of Neurology
Dr.Aumir Moin
Consultant Neurologist
Dr. K.S. Bopaiah
Consultant Neuro& Spine surgeon
Dr.Lokesh B.L.
Consultant Neuro & Spine Surgeon

Dr. K.S. Bopaiah

MBBS, DNB(Neurosurgery)

Consultant Neuro& Spine surgeon


Dr. Bopaiah, a Consultant Neuro& Spine surgeon at Apollo hospitals Bangalore. He has rich experience in the field of Neurosurgery.


  • Headed the Dept of Neurosurgery, OPEC Hospital,Raichur (150 bedded Superspecialty hospital jointly managed by Govt of Karnataka and Apollo Hospitals Group).
  • Ha has an overall experience of 9 years as consultant Neuro and Spine surgeon and has got 6 years experience in Apollo Mysore.


Specialty Interest

  • Microneurosurgery
    • VascularNeurosurgery – Aneurysm / AVM
    • Brain / Spinal Tumors
    • Paediatric Neurosurgery
  • Neuro-endoscopy
  • Trauma

Publications & Projects

  • R.R Ravi, K S Bopaiah, et al. Ravi Rectangle. J. Spinal Surg 2010; 2(2): 415-17 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial, Lancet Online, June 15,2010, DOI:10.1016/S0140-6736(10)60835-5.
  • Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients-BMJ, Feb 2008; 336: 425 - 429. Final results of MRC CRASH, a randomized placebo-controlled trial of intravenous corticosteroid in adults with head injury- Outcome at 6months. Lancet 2005; 365:1957-59.
  • Effect of intravenous corticosteroid on death within 14 days in 10008 adults with clinically significant head injury: Randomized placebo-controlled trial. Lancet 2004; 364:1321-28.
  • Update on progress in the international, multicenter, randomized, controlled trial of corticosteroids after significant head injury (Medical Research Council CRASH Trial) - Current Opinion in Critical Care. 9(2):92-97, April 2003.
  • Phase II Project – A prospective study to correlate gene signatures with clinical outcome of Astrocytomas and identification of potential targets at NIMHANS under Council of Scientific & Industrial Research (CSIR), New Delhi.
  • BRAIN TRIAL – Bradykinin beta 2 Receptor Antagonist InNeurotrauma Phase II randomized double blind placebo controlled dose finding safety & tolerability trial of XY2405 (Bradykinin beta 2 Receptor Antagonist) as a treatment for Traumatic brain injury.
  • CRASH 2 – (Clinical Randomization of an Anti-fibrinolytic in Significant Hemorrhage) Randomized placebo controlled trial of the effect of early transfusion of Tranexamic Acid on death & transfusionrequirement in patients with significant hemorrhage or at risk of significant hemorrhage.
  • CRASH 1 – (Corticosteroid Randomization AfterSignificant Head injury) Randomized placebo controlled trial among adults with head injury and impaired consciousness, of the effects of a 48 hour infusion of corticosteroids on death and neurological disability.